J. Perhach

发表

Lack of Effect of Azelastine and Ketoconazole Coadministration on Electrocardiographic Parameters in Healthy Volunteers

W. Trager, J. Morganroth, R. Levy, 1997, Journal of clinical pharmacology.

Acamprosate: Safety and Tolerability in the Treatment of Alcohol Dependence

R. Rosenthal, J. Perhach, A. Goodman, 2008, Journal of addiction medicine.

Safety and Efﬁcacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension

R. Palmer, A. Hardan, R. Findling, 2016 .

Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.

J. Weiler, L. Diamond, J. T. Connell, 1988, The Journal of allergy and clinical immunology.

Pharmacodynamic evaluation of azelastine in subjects with asthma.

S. Spector, G. Rachelefsky, R. Katz, 1987, The Journal of allergy and clinical immunology.

A dose-response study of the bronchodilator action of azelastine in asthma.

S. Spector, J. Kemp, E. Meltzer, 1987, The Journal of allergy and clinical immunology.

Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells.

R. Sofia, J. Perhach, N. Chand, 1984, The Journal of allergy and clinical immunology.

Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action.

R. Sofia, J. Perhach, N. Chand, 1983, European journal of pharmacology.

Heterogeneity of calcium channels in mast cells and basophils and the possible relevance to pathophysiology of lung diseases: A review

R. Sofia, J. Perhach, N. Chand, 1986, Agents and Actions.

251 Azelastine (azel) in the treatment of asthma

S. Spector, J. Kemp, E. Middleton, 1985 .

Perspective of the Pharmaceutical Industry

L. Kramer, J. Perhach, 1990 .

Inhibition of Leukotriene (SRS‐A)‐Mediated Acute Lung Anaphylaxis by Azelastine in Guinea Pigs

R. Sofia, J. Perhach, N. Chand, 1986, Allergy.

Efficacy of azelastine in perennial allergic rhinitis: clinical and rhinomanometric evaluation.

W. Pierson, E. Meltzer, L. Cummins, 1988, The Journal of allergy and clinical immunology.

Comment: Warfarin—Felbamate Interaction

P. Glue, R. Colucci, J. Perhach, 1994, The Annals of pharmacotherapy.

241 Inhibition of leukotriene (SRS-A)-mediated allergic bronchospasm by azelastine, a novel orally effective antiasthmatic drug

R. Sofia, J. Perhach, N. Chand, 1983 .

Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial.

R. Hofbauer, J. Saxton, M. Woodward, 2012, Journal of Alzheimer's disease : JAD.

Pharmacokinetic Interactions with Felbamate

P. Glue, C. Banfield, R. Levy, 1997, Clinical pharmacokinetics.

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

J. Sackellares, M. Sperling, F. Dreifuss, 1993, The New England journal of medicine.

The effect of felbamate on valproic acid disposition

I. Leppik, R. Shumaker, D. Ward, 1994, Clinical pharmacology and therapeutics.

The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling.

P. Glue, C. Banfield, M. Affrime, 1996, Therapeutic drug monitoring.

Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro.

C. D. Thompson, I. Kapetanovic, T. Macdonald, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Tolerability and Pharmacokinetics of Monotherapy Felbamate Doses of 1,200–6,000 mg/day in Subjects with Epilepsy

R. Sachdeo, A. Rosenberg, W. Lyness, 1997, Epilepsia.

Evaluation of the Potential Interaction Between Felbamate and Erythromycin in Patients with Epilepsy

P. A. Montgomery, R. Sachdeo, R. Shumaker, 1998, Journal of clinical pharmacology.

The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers

S. Waldman, W. Kraft, H. Greenberg, 2007, Journal of clinical pharmacology.

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension

R. Palmer, A. Hardan, R. Findling, 2017, Journal of child and adolescent psychopharmacology.

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

F. Manes, R. Allegri, G. Grossberg, 2013, CNS Drugs.

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease

M. Weiner, C. Sadowsky, R. Hofbauer, 2011, Alzheimer's & Dementia.

Antihistamines: Findings in Clinical Trials Relevant to Therapeutics

J. T. Connell, William W. Dressier, J. Perhach, 1987 .

Clinical experience with flupirtine in the U.S.

F. Mcmahon, J. Newton, J. Perhach, 1987, Postgraduate medical journal.

Corticosteroid-sparing effect of azelastine in the management of bronchial asthma.

J. Weiler, R. Dockhorn, W. Busse, 1996, American journal of respiratory and critical care medicine.

Quantification in Patient Urine Samples of Felbamate and Three Metabolites: Acid Carbamate and Two Mercapturic Acids

C. D. Thompson, T. A. Miller, G. Montouris, 1999, Epilepsia.

P4-405: A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer's disease

F. Manes, R. Allegri, L. M. G. Robledo, 2008, Alzheimer's & Dementia.